Abbvie Inc.

North Chicago, IL, United States

Abbvie Inc.

North Chicago, IL, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Abbvie Inc. | Date: 2017-01-27

The instant invention relates to the field of protein production, and in particular to compositions and processes for controlling and limiting the heterogeneity of proteins expressed in host cells.


The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.


Patent
Abbvie Inc. | Date: 2017-02-08

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.


Patent
Abbvie Inc. and Apogenix | Date: 2017-03-01

Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.


Patent
Abbvie Inc. | Date: 2017-01-18

The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.


Patent
Abbvie Inc. | Date: 2017-05-17

Adapters for a connector assembly for percutaneous tubing are provided. A male adapter (fig. 22a, 1000) includes a connector fitting (1002) proximate a first end, the connector fitting configured to join to a connector for a tubing system or device, and a male connector (656) proximate a second end. The male connector includes a plug end with a fluid lumen defined therethrough, the plug end having a circumferential groove defined therein to receive a locking extension of a female connector sized to be received within the circumferential groove of the plug end to allow the female connector to rotate relative to and maintain axial engagement with the male connector when the locking extension is received within the groove. An adapter having a female connector (fig. 24, 1300) is also provided.


Patent
Abbvie Inc., Walter and Eliza Hall Institute of Medical Research | Date: 2017-01-04

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.


Patent
AbbVie B.V. and Abbvie Inc. | Date: 2017-03-22

The present invention relates spiro-cyclic amine derivatives of the formula (I)R1 is selected fromcyano,(2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkyl each optionally substituted with CN or one or more fluoro atoms,(3-6C)cycloalkyl, (4-6C)cycloalkenyl or a (8-10C)bicyclic group, each optionally substituted with halogen or (1-4C)alkyl,phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, cyano, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (1-6C)alkoxy optionally substituted with one or more fluoro atoms, amino, di(1-4C)alkylamino and (3-6C)cycloalkyl optionally substituted with phenyl which may be substituted with (1-4C)alkyl or halogen,phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl optionally substituted with one or more fluoro atoms,monocyclic heterocycle optionally independently substituted with halogen, (1-6C)alkyl optionally substituted with one or more fluoro atoms, (3-6C)cycloalkyl, or phenyl optionally substituted with (1-4C)alkyl or halogen,andbicyclic heterocycle optionally substituted with halogen or (1-4C)alkyl optionally substituted with one or more fluoro atoms;-Y-(C_(n)-alkylene)-X- is a linking group whereinY is attached to R1 and selected from a bond, -O-, -CO-, -S-, -SO-, -SO_(2)-, -NH-, -CH=CH-, -C(CF_(3))=CH-, -CC-, -CH_(2)-O-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, and trans-cyclopropylene;n is an integer from 0 to 10; andX is attached to the phenylene/pyridyl moiety and selected from a bond, -O-, -S-, -SO-, -SO_(2)-, -NH-, -CO-, -CH=CH-, and trans-cyclopropylene;R2 is H or independently selected from one or more substituents selected from halogen, (1-4C)alkoxy and (1-4C)alkyl optionally substituted with one or more fluor atoms; andR3 is (1-4C)alkylene-R4 wherein the alkylene group may be substituted with one or more halogen atoms or with (CH_(2))_(2) to form a cyclopropyl moiety, or R3 is (3-6C)cycloalkylene-R4, -CH_(2)-(3-6C)cycloalkylene-R4, (3-6C)cycloalkylene-CH_(2)-R4 or -CO-CH_(2)-R4, wherein R4 is -OH, -PO_(3)H_(2), -OPO_(3)H_(2), -COOH, -COO(1-4C)alkyl or tetrazol-5-yl;Q is a bond or -O-;-W-T- is selected from -CH=CH-, -CH_(2)-CH_(2)-, -CH_(2)-O-, -O-CH_(2)-, -O-CH_(2)-CH_(2)-, and -CO-O-;R5 is H or independently selected from one or more halogens;Z is CH, CR2 or N; andA represents a morpholine ring structure or a 5-, 6- or 7-membered cyclic amine;or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor(s) is (are) involved.


Patent
Abbvie Inc. and AbbVie Deutschland GmbH & Co. KG | Date: 2017-02-01

The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The invention further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed composition, wherein the pre-shaped bodies are interconnected by flash.


Patent
Abbvie Inc. and Dana-Farber Cancer Institute | Date: 2017-01-11

Composition suitable for treating multiple myeloma in subject, comprising a therapeutically effective amount of HuLuc63, a therapeutically effective amount of lenalidomide and/or bortezomib, and a pharmaceutically acceptable carrier, wherein said composition is capable of being administered in a single or multiple dose regimen.

Loading Abbvie Inc. collaborators
Loading Abbvie Inc. collaborators